Phosphorus dendrimers affect Alzheimer's (Aβ1-28) peptide and MAP-Tau protein aggregation.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Molecular Pharmaceutics

• Publication date

  2012-01-13

• Fields of study

  Medicine, Materials Science, Chemistry

• Identifiers
  DOI 10.1021/mp2005627PMID 22206488
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mechanistic studies of in vitro cytotoxicity of poly(amidoamine) dendrimers in mammalian cells.

  2010cited by this paper
• Influence of surface functionality of poly(propylene imine) dendrimers on protease resistance and propagation of the scrapie prion protein.

  2010cited by this paper
• Mitochondria, cholesterol and amyloid β peptide: a dangerous trio in Alzheimer disease

  2009cited by this paper
• Dendrimers as versatile platform in drug delivery applications.

  2009cited by this paper
• How to study dendriplexes I: Characterization.

  2009cited by this paper
• Neuronal calcium mishandling and the pathogenesis of Alzheimer's disease.

  2008cited by this paper
• Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease.

  2008cited by this paper
• The influence of densely organized maltose shells on the biological properties of poly(propylene imine) dendrimers: new effects dependent on hydrogen bonding.

  2008cited by this paper
• Cytosolic Abnormally Hyperphosphorylated Tau But Not Paired Helical Filaments Sequester Normal MAPs and Inhibit Microtubule Assembly

  2008cited by this paper
• Endocytosis and Interaction of Poly (Amidoamine) Dendrimers with Caco-2 Cells

  2007cited by this paper
• Influence of phosphorus dendrimers on the aggregation of the prion peptide PrP 185-208.

  2007cited by this paper
• Targeted polyphosphatase expression alters mitochondrial metabolism and inhibits calcium-dependent cell death

  2007cited by this paper
• Tau-mediated neurodegeneration in Alzheimer's disease and related disorders

  2007cited by this paper
• Molecular interactions of dendrimers with amyloid peptides: pH dependence.

  2006cited by this paper
• Influence of heparin and dendrimers on the aggregation of two amyloid peptides related to Alzheimer's and prion diseases.

  2006cited by this paper
• Water-soluble phosphorus-containing dendrimers

  2005cited by this paper
• Cationic phosphorus-containing dendrimers reduce prion replication both in cell culture and in mice infected with scrapie.

  2004cited by this paper
• Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs

  2004cited by this paper
• Small assemblies of unmodified amyloid β-protein are the proximate neurotoxin in Alzheimer’s disease

  2004cited by this paper
• Transport of dendrimer nanocarriers through epithelial cells via the transcellular route.

  2004cited by this paper
• Oligomers on the brain: the emerging role of soluble protein aggregates in neurodegeneration.

  2004cited by this paper
• Convergence of atherosclerosis and Alzheimer's disease: inflammation, cholesterol, and misfolded proteins.

  2004cited by this paper
• Water-Soluble Polycationic Dendrimers with a Phosphoramidothioate Backbone: Preliminary Studies of Cytotoxicity and Oligonucleotide/Plasmid Delivery in Human Cell Culture

  2003cited by this paper
• Interactions between PAMAM dendrimers and bovine serum albumin.

  2003cited by this paper
• Transport mechanism(s) of poly (amidoamine) dendrimers across Caco-2 cell monolayers.

  2003cited by this paper
• Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution

  2003cited by this paper
• Neuropathologic changes in Alzheimer's disease.

  2003cited by this paper
• Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders.

  2003cited by this paper
• Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases

  2002cited by this paper
• Gamma-secretase inhibition.

  2002cited by this paper
• Identification of a Common Sphingolipid-binding Domain in Alzheimer, Prion, and HIV-1 Proteins*

  2002cited by this paper
• Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition.

  2002cited by this paper
• Biological applications of dendrimers.

  2002cited by this paper
• Neurodegenerative tauopathies.

  2001cited by this paper
• Amyloid-β oligomers: their production, toxicity and therapeutic inhibition

  2001cited by this paper
• Branched Polyamines Cure Prion-Infected Neuroblastoma Cells

  2001cited by this paper
• Poly(amidoamine) (PAMAM) dendrimers: from biomimicry to drug delivery and biomedical applications.

  2001cited by this paper
• The structural basis of protein folding and its links with human disease.

  2001cited by this paper
• Intraneuronal Abeta42 accumulation in human brain.

  2000cited by this paper
• Tau protein isoforms, phosphorylation and role in neurodegenerative disorders.

  2000cited by this paper
• Intraneuronal Aβ42 Accumulation in Human Brain

  2000cited by this paper
• Amyloid fibrillogenesis: themes and variations.

  2000cited by this paper
• Estimation of protein secondary structure from circular dichroism spectra: comparison of CONTIN, SELCON, and CDSSTR methods with an expanded reference set.

  2000cited by this paper
• Estimation of protein secondary structure from circular dichroism spectra: inclusion of denatured proteins with native proteins in the analysis.

  2000cited by this paper
• Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier.

  2000cited by this paper
• PREPARATION OF WATER-SOLUBLE CATIONIC PHOSPHORUS-CONTAINING DENDRIMERS AS DNA TRANSFECTING AGENTS

  1999cited by this paper
• Protein misfolding, evolution and disease.

  1999cited by this paper
• Rapid assembly of Alzheimer-like paired helical filaments from microtubule-associated protein tau monitored by fluorescence in solution.

  1998cited by this paper
• Activation of the Wnt signaling pathway: a molecular mechanism for lithium action.

  1997cited by this paper
• 1La and 1Lb transitions of tryptophan: applications of theory and experimental observations to fluorescence of proteins.

  1997cited by this paper
• Polymerization of τ into Filaments in the Presence of Heparin: The Minimal Sequence Required for τ ‐ τ Interaction

  1996cited by this paper
• Assembly of microtubule-associated protein tau into Alzheimer-like filaments induced by sulphated glycosaminoglycans

  1996cited by this paper
• Polymerization of tau into filaments in the presence of heparin: the minimal sequence required for tau-tau interaction.

  1996cited by this paper
• Production of the Alzheimer amyloid beta protein by normal proteolytic processing.

  1992cited by this paper
• Quantitative analysis of protein far UV circular dichroism spectra by neural networks.

  1992cited by this paper
• Validation of the MTT dye assay for enumeration of cells in proliferative and antiproliferative assays.

  1992cited by this paper
• The Consortium to Establish a Registry for Alzheimer's Disease (CERAD)

  1991cited by this paper
• Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill.

  1989cited by this paper
• Calculation of protein conformation from circular dichroism.

  1986cited by this paper
• Chapter 2 – Circular Dichroism of Peptides

  1985cited by this paper
• A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

  1976cited by this paper

• Phosphorus-containing dendrimers: Another type of phosphorus polymers, and their properties

  2025cites this paper
• β-Amyloid: Structure, Properties, and Link with Alzheimer’s Disease

  2025cites this paper
• On topological aspects of phosphorus dendrimers using edge cut method

  2025cites this paper
• Fully biodegradable dendrimers as novel nanodrugs for amyloid-β-induced neurotoxicity.

  2025cites this paper
• Factors Affecting Pathological Amyloid Protein Transformation: From Post-Translational Modifications to Chaperones

  2025cites this paper
• Design, synthesis and in vitro evaluations of new cyclotriphosphazenes as safe drug candidates.

  2025cites this paper
• Biocompatibility of Phosphorus Dendrimers and Their Antibacterial Properties as Potential Agents for Supporting Wound Healing

  2025cites this paper
• Structurally programmable, functionally tuneable dendrimers in biomedical applications.

  2025cites this paper
• Therapeutic Dendrimers: a Nanotechnology Approach to Alzheimer’s Disease

  2025cites this paper
• Molecular insights into the phase transition of lysozyme into amyloid nanostructures: Implications of therapeutic strategies in diverse pathological conditions.

  2024cites this paper
• Prion protein prevents the inhibition of large-conductance calcium-activated potassium channel by Tau peptide K18 oligomers.

  2024cites this paper
• Dendrimers in Neurodegenerative Diseases

  2023cites this paper
• Dendrimers: Patents for Alzheimer's Disease.

  2023cites this paper
• Dendrimers and Derivatives as Multifunctional Nanotherapeutics for Alzheimer’s Disease

  2023influential citation
• Phosphorus-carrying cascade molecules: inner architecture to biomedical applications

  2023cites this paper
• Neuro degenerative disease and brain delivery of therapeutics: Bridging the gap using dendrimers

  2023cites this paper
• siRNA drug delivery across the blood-brain barrier in Alzheimer's Disease.

  2023cites this paper
• A critical review on the role of nanotheranostics mediated approaches for targeting β amyloid in Alzheimer’s

  2023cites this paper
• Dendrimer: An update on recent developments and future opportunities for the brain tumors diagnosis and treatment

  2023cites this paper
• Recent Trend of Nano-Particulate Carriers for the Diagnosis and Treatment of Alzheimer's disease.

  2022cites this paper
• Dendrimer nanoplatforms for veterinary medicine applications: a concise overview.

  2022cites this paper
• Multiple approaches for the management of Alzheimer disease: Natural compounds, FDA approved drugs, and nanotechnology interventions.

  2022cites this paper
• Enhancing Neurological Competence of Nanoencapsulated Cordyceps/Turmeric Extracts in Human Neuroblastoma SH-SY5Y Cells

  2022cites this paper
• Update on Therapeutic potential of emerging nanoformulations of phytocompounds in Alzheimer's and Parkinson's disease

  2022cites this paper
• Effect of amphiphilic phosphorous dendrons on the conformation, secondary structure, and zeta potential of albumin and thrombin

  2022cites this paper
• Dendrimers in the context of targeting central nervous system disorders

  2022cites this paper
• Dendrimers as Antiamyloid Agents

  2022cites this paper
• Facile Synthesis of Amphiphilic Fluorescent Phosphorus Dendron-Based Micelles as Antiproliferative Agents: First Investigations.

  2021cites this paper
• Hybrid phosphorus–viologen dendrimers as new soft nanoparticles: design and properties

  2021cites this paper
• Types of dendrimers

  2021cites this paper
• Neurotoxicity of oligomers of phosphorylated Tau protein carrying tauopathy-associated mutation is inhibited by prion protein.

  2021cites this paper
• Dendrimer Architectonics to Treat Cancer and Neurodegenerative Diseases with Implications in Theranostics and Personalized Medicine.

  2021cites this paper
• In vitro and in vivo models for anti-amyloidosis nanomedicines.

  2021cites this paper
• Breaking Barriers: Bioinspired Strategies for Targeted Neuronal Delivery to the Central Nervous System

  2020cites this paper
• Nanotechnology-based Targeting of Neurodegenerative Disorders: A Promising Tool for Efficient Delivery of Neuromedicines.

  2020cites this paper
• In vivo therapeutic applications of phosphorus dendrimers: state of the art.

  2020cites this paper
• Nanomedicine against Alzheimer's and Parkinson's disease.

  2020cites this paper
• Phosphorus Dendrimers as Nanotools against Cancers†

  2020cites this paper
• Neuroprotective Effect of New Nanochelating-Based Nano Complex, ALZc3, Against Aβ (1–42)-Induced Toxicity in Rat: a Comparison with Memantine

  2020cites this paper
• Dendrimer-Based Drug Delivery Systems for Brain Targeting

  2019cites this paper
• Alzheimer’s Disease – Future Therapy Based on Dendrimers

  2019cites this paper
• Targeted human cytolytic fusion proteins at the cutting edge: harnessing the apoptosis-inducing properties of human enzymes for the selective elimination of tumor cells

  2019cites this paper
• Cytotoxicity of Dendrimers

  2019cites this paper
• Overcoming the Blood–Brain Barrier. Challenges and Tricks for CNS Drug Delivery

  2019cites this paper
• Nanoneuromedicine for management of neurodegenerative disorder

  2019cites this paper
• Inorganic Dendrimers and Their Applications

  2019cites this paper
• Using a portable total reflection X‐ray fluorescence system for a multielement analysis of Swiss mice brains with experimental Alzheimer's disease induced by β‐amyloid oligomers

  2019cites this paper
• Dendrimers and hyperbranched structures for biomedical applications

  2019cites this paper
• 110th Anniversary: Nanoparticle mediated drug delivery for the treatment of Alzheimer's disease: Crossing the blood-brain barrier.

  2019cites this paper
• Dendrimers in the context of nanomedicine.

  2019cites this paper
• Synthesis and anticancer activity of cyclotriphosphazenes functionalized with 4-methyl-7-hydroxycoumarin

  2019cites this paper
• Multivalent interacting glycodendrimer to prevent amyloid-peptide fibril formation induced by Cu(II): A multidisciplinary approach

  2018cites this paper
• Interaction of Polymers with Amyloidogenic Peptides

  2018cites this paper
• Dendrimers as Drug Nanocarriers: The Future of Gene Therapy and Targeted Therapies in Cancer

  2018cites this paper
• Cyclotriphosphazene core-based dendrimers for biomedical applications: an update on recent advances.

  2018cites this paper
• Amyloidogenic cross-seeding of Tau protein: Transient emergence of structural variants of fibrils

  2018cites this paper
• The Delivery Challenge in Neurodegenerative Disorders: The Nanoparticles Role in Alzheimer’s Disease Therapeutics and Diagnostics

  2018cites this paper
• Phosphorhydrazones as Useful Building Blocks for Special Architectures: Macrocycles and Dendrimers

  2018cites this paper
• Dendrimers as Powerful Building Blocks in Central Nervous System Disease: Headed for Successful Nanomedicine

  2018cites this paper
• Reply to the Reviewer’s Comments

  2018cites this paper
• Can dendrimer based nanoparticles fight neurodegenerative diseases? Current situation versus other established approaches

  2017cites this paper
• Human MAP Tau Based Targeted Cytolytic Fusion Proteins

  2017cites this paper
• New Fully Biodegradable PEG-Dendrimers: Synthesis and evaluation as siRNA vectors

  2017cites this paper
• Nanotechnology Based Theranostic Approaches in Alzheimer's Disease Management: Current Status and Future Perspective.

  2017influential citation
• Nanobiomaterials’ applications in neurodegenerative diseases

  2017cites this paper
• Nanoscience in Targeted Brain Drug Delivery

  2017cites this paper
• Biomedical Applications of Acridines

  2017cites this paper
• Nanotechnology‐based drug delivery systems for Alzheimer's disease management: Technical, industrial, and clinical challenges

  2017cites this paper
• Low Serum Phosphorus Correlates with Cerebral Aβ Deposition in Cognitively Impaired Subjects: Results from the KBASE Study

  2017cites this paper
• Anticancer copper(II) phosphorus dendrimers are potent proapoptotic Bax activators.

  2017cites this paper
• Phosphorus dendrimers for nanomedicine.

  2017cites this paper
• pH-Dependent In-Cell Self-Assembly of Peptide Inhibitors Increases the Anti-Prion Activity While Decreasing the Cytotoxicity.

  2017cites this paper
• Applications for Treatment of Neurodegenerative Diseases

  2017cites this paper
• Low generation anionic dendrimers modulate islet amyloid polypeptide self-assembly and inhibit pancreatic β-cell toxicity

  2016cites this paper
• Effect of Dendrimers and Dendriplexes on Model Lipid Membranes

  2016cites this paper
• Effect of dendrimers on selected enzymes--Evaluation of nano carriers.

  2016cites this paper
• Application of Nanomedicine to the CNS Diseases.

  2016cites this paper
• Inorganic dendrimers: recent advances for catalysis, nanomaterials, and nanomedicine.

  2016cites this paper
• Nanomaterials for Neurology: State-of-the-Art.

  2016cites this paper
• Synthesis and characterization of bifunctional dendrimers: preliminary use for the coating of gold surfaces and the proliferation of human osteoblasts (HOB)

  2015cites this paper
• Fluorescent Phosphorus Dendrimer as a Spectral Nanosensor for Macrophage Polarization and Fate Tracking in Spinal Cord Injury.

  2015cites this paper
• Phosphorus-Based Dendrimer ABP Treats Neuroinflammation by Promoting IL-10-Producing CD4(+) T Cells.

  2015cites this paper
• Electrogenerated chemiluminescence reactions between the [Ru(bpy)3](2+) complex and PAMAM GX.0 dendrimers in an aqueous medium.

  2015cites this paper
• Investigations on dendrimer space reveal solid and liquid tumor growth-inhibition by original phosphorus-based dendrimers and the corresponding monomers and dendrons with ethacrynic acid motifs.

  2015cites this paper
• Etude de l'interaction de dendrimères phosphorés avec les monocytes humains : recherche de récepteur (s)

  2015cites this paper
• Dendritic glycopolymers based on dendritic polyamine scaffolds: view on their synthetic approaches, characteristics and potential for biomedical applications.

  2015cites this paper
• Cationic phosphorus dendrimers and therapy for Alzheimer's disease

  2015cites this paper
• Dendrimer space exploration: an assessment of dendrimers/dendritic scaffolding as inhibitors of protein-protein interactions, a potential new area of pharmaceutical development.

  2014cites this paper
• HIV-antigens charged on phosphorus dendrimers as tools for tolerogenic dendritic cells-based immunotherapy.

  2014cites this paper
• Dendrimer advances for the central nervous system delivery of therapeutics.

  2014cites this paper
• Nanotechnology Building Blocks for Intervention with Alzheimer's Disease Pathology: Implications in Disease Modifying Strategies

  2014cites this paper
• Nanoparticles for Diagnosis and/or Treatment of Alzheimer's Disease

  2014cites this paper
• A viologen phosphorus dendritic molecule as a carrier of ATP and Mant-ATP: spectrofluorimetric and NMR studies

  2014cites this paper
• Self-assembly of Cu(II) with amyloid β19–20 peptide: relevant to Alzheimer's disease

  2014cites this paper
• Influence of surface groups on poly(propylene imine) dendrimers antiprion activity.

  2013cites this paper
• Dendrimers as macromolecular tools to tackle from colon to brain tumor types: a concise overview

  2013cites this paper
• Promising Low-Toxicity of Viologen-Phosphorus Dendrimers against Embryonic Mouse Hippocampal Cells

  2013cites this paper
• Nanomedicine for prion disease treatment

  2013cites this paper
• Nanotechnology-Based Drug Delivery Systems for Targeting, Imaging and Diagnosis of Neurodegenerative Diseases

  2013cites this paper
• Positively charged phosphorus dendrimers. An overview of their properties

  2013cites this paper